IFNA1 and depressive disorder: Despite these limitations, our meta-analysis of double-blind, placebo-controlled RCTs shows that prophylactic SSRIs can significantly reduce the incidence of PEG-IFN-α/RBV-associated depression in patients with CHC, with good safety and tolerability and without reduction of SVR.